Keith Jendza

USPTO Granted Patents = 23 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 8.8

ph-index = 5

Forward Citations = 222(Granted Patents)

Location History:

San Francisco, CA (US) (2010 - 2014)
Boston, MA (US) (2012 - 2023)

Company Filing History:

Theravance Biopharma R&d Ip, LLC

patents

Years Active: 2010-2024

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12129246 - Hydroquinazoline derivatives for the treatment of a disease or disorder (2024-10-29),

2. 12122761 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2024-10-22),

3. 11820778 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2023-11-21),

4. 11548865 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2023-01-10),

5. 11485742 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2022-11-01),

6. 9676728 - 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof (2017-06-13),

7. 9475806 - Complement factor B inhibitors and uses there of (2016-10-25),

8. 9198899 - Dual-acting benzoimidazole antihypertensive agents (2015-12-01),

9. 9150514 - Dual-acting antihypertensive agents (2015-10-06),

10. 9056874 - Complement pathway modulators and uses thereof (2015-06-16),

11. 8895755 - Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity (2014-11-25),

12. 8735625 - Dual-acting antihypertensive agents (2014-05-27),

13. 8637676 - Dual-acting benzoimidazole antihypertensive agents (2014-01-28),

14. 8569351 - Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity (2013-10-29),

15. 8394846 - Dual-acting antihypertensive agents (2013-03-12),

Title: Keith Jendza: Innovator in Pharmaceutical Patents

Introduction

Keith Jendza, based in Boston, MA, is a notable inventor with an impressive portfolio of 23 patents. His innovative work primarily revolves around pharmaceutical compounds designed to treat various diseases and disorders. Jendza's contributions to the field have greatly impacted drug development and therapeutic approaches.

Latest Patents

Among his latest patents, Jendza has developed hydroquinazoline derivatives aimed at treating specific diseases. This invention discloses a compound characterized by Formula (I) and includes compositions and methods for utilizing these compounds effectively. Another significant patent involves 2-azaspiro[3.4]octane derivatives, which serve as M4 receptor agonists. The disclosure focuses on compounds defined by Formula (I) and encompasses pharmaceutical compositions that incorporate these compounds.

Career Highlights

Jendza's professional journey includes impactful stints at major pharmaceutical companies, such as Theravance, Inc. and Novartis AG. His experiences in these organizations have enriched his understanding of the pharmaceutical landscape, driving his innovative spirit and expertise in patentable technologies.

Collaborations

Throughout his career, Keith has collaborated with distinguished professionals in the field, including Seok-Ki Choi and Paul Ross Fatheree. These partnerships have fostered a creative environment that encourages innovation and the development of groundbreaking solutions.

Conclusion

Keith Jendza stands out as a prolific inventor in the pharmaceutical industry, with a commendable number of patents that reflect his dedication to advancing medicine. His latest innovations demonstrate a commitment to improving treatment options, showcasing his significant contribution to healthcare through the power of invention.

This text is generated by artificial intelligence and may not be accurate.